EG245440 Inhibitors
Gm4988, a predicted gene with putative DNA-binding transcription factor activity, is associated with RNA polymerase II-specific regulatory functions. While its precise role remains unclear, potential regulators have been identified through the exploration of chemical inhibitors. The inhibitors exert their influence either directly on Gm4988 or indirectly by modulating key signaling pathways. Inhibition of the MAPK pathway, achieved by compounds such as Selumetinib, PD0325901, and SB203580, emerges as a common theme. These inhibitors disrupt downstream signaling cascades, potentially altering the expression and function of Gm4988. Similarly, LY294002 and Wortmannin, targeting the PI3K/AKT pathway, may indirectly affect Gm4988 by perturbing intracellular signaling connected to PI3K/AKT-mediated processes.
Epigenetic regulation is another avenue explored through inhibitors like JQ1 and SP2509, which target bromodomains, potentially impacting Gm4988 by modulating chromatin accessibility. Furthermore, BAY 11-7082 inhibits NF-κB, potentially influencing Gm4988 transcriptional regulation in various cellular contexts. Cisplatin-induced DNA damage, the inhibition of GSK-3 by SB216763 affecting the Wnt pathway, and other compounds targeting JNK and mTOR contribute to the spectrum of potential Gm4988 regulators. In summary, the exploration of these inhibitors provides a starting point for unraveling the functional intricacies of Gm4988 and sheds light on the interconnected signaling pathways that may govern its expression and activity in diverse cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, a MEK inhibitor, disrupts the MAPK pathway. By inhibiting MEK, it indirectly influences Gm4988 expression and function through altered intracellular signaling cascades, impacting the regulatory mechanisms associated with the MAPK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, a key kinase in the PI3K/AKT pathway. Through disruption of this pathway, it indirectly affects Gm4988, influencing its expression and function by perturbing intracellular signaling cascades connected to PI3K/AKT-mediated cellular processes. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a bromodomain inhibitor, disrupts BET proteins' interaction with chromatin. As Gm4988 may be regulated epigenetically, JQ1's impact on chromatin accessibility indirectly influences Gm4988 expression, potentially modulating its function through altered transcriptional regulation mechanisms. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that affects the PI3K/AKT pathway. Its inhibition disrupts downstream signaling cascades, indirectly influencing Gm4988 by altering cellular processes connected to PI3K/AKT, potentially affecting its expression and function through perturbed intracellular signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By targeting p38 MAPK, it influences the MAPK signaling pathway. This indirect inhibition may impact Gm4988, as the MAPK pathway is interconnected with various cellular processes, potentially affecting its expression and function through altered signaling cascades. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin induces DNA damage, affecting cellular processes. Indirectly, this can impact Gm4988 by disrupting cellular homeostasis, potentially influencing its expression and function through altered regulatory mechanisms related to DNA damage response pathways. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, disrupting downstream signaling. As Gm4988 may be influenced by NF-κB, its inhibition can indirectly affect Gm4988 expression and function by altering the transcriptional regulation mediated by NF-κB in various cellular contexts. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cellular processes. By influencing mTOR signaling, it indirectly impacts Gm4988, potentially altering its expression and function through disrupted intracellular signaling pathways related to mTOR-mediated cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, a member of the MAPK family. Its impact on the MAPK pathway indirectly influences Gm4988, potentially affecting its expression and function through altered signaling cascades associated with JNK-mediated cellular responses. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509, a BET bromodomain inhibitor, disrupts chromatin interactions. As Gm4988 may be subject to epigenetic regulation, SP2509's influence on chromatin accessibility indirectly impacts Gm4988 expression, potentially modulating its function through altered transcriptional regulation. | ||||||